The new leader of the CD­C's flag­ship vac­cine ad­vi­so­ry group re­cent­ly claimed that Covid-19 vac­cines were re­spon­si­ble for a rise in can­cer cas­es, and that the vast ma­jor­i­ty of women who get the vac­cine in their first trimester have mis­car­riages.

The com­ments by Kirk Mil­hoan, who serves as chair­man of the CD­C's Ad­vi­so­ry Com­mit­tee on Im­mu­niza­tion Prac­tices, were made at a Texas church and post­ed on YouTube in Oc­to­ber. Mil­hoan al­so com­pared pan­dem­ic-era vac­ci­na­tion record cards to Jews who were forced to wear spe­cif­ic arm­bands dur­ing the Holo­caust.

"And what they said is, if you did­n't get the vac­cine, then you were dirty, right? So that brings up all the is­sues of what hap­pened when the Jews had to wear the yel­low Star of David, right? They were the dirty ones," he said in the video.

A top FDA of­fi­cial's claim that Covid vac­cines caused at least 10 deaths in chil­dren has yet to be backed up by the da­ta that typ­i­cal­ly ac­com­pa­ny ma­jor safe­ty an­nounce­ments, in­clud­ing de­tails of the al­leged deaths, which vac­cines were used, and case re­ports that could help clin­i­cians and re­searchers make their own as­sess­ments.

The claim, made in a lengthy email to staff on Fri­day by CBER Di­rec­tor Vinay Prasad, de­scribes the al­leged deaths as "a pro­found rev­e­la­tion" about the safe­ty of the shots. It al­so calls for sig­nif­i­cant changes to the reg­u­la­tion of child­hood vac­cine ap­provals, and comes just days be­fore HHS Sec­re­tary Robert F. Kennedy Jr.'s hand­picked group of CDC ad­vi­sors will dis­cuss the child­hood vac­cine sched­ule — and po­ten­tial­ly rec­om­mend changes to the prac­tice of giv­ing the he­pati­tis B vac­cine soon af­ter birth.

Be­lite Bio re­port­ed Mon­day that its pill for Star­gardt dis­ease suc­ceed­ed in a Phase 3 tri­al, and it's head­ing to the FDA to seek ap­proval.

There are cur­rent­ly no ap­proved treat­ments for the rare ge­net­ic eye con­di­tion, which leads to loss of vi­sion and blind spots, among oth­er symp­toms. The dis­ease typ­i­cal­ly man­i­fests in chil­dren and teenagers, and cen­tral vi­sion loss pro­gress­es over decades. Be­lite is con­tend­ing that its drug, known as tin­lare­bant, can slow the dis­ease in young peo­ple by re­duc­ing the buildup of cer­tain tox­ins in the eye.

For the Phase 3 DRAG­ON tri­al, Be­lite re­cruit­ed pa­tients be­tween the ages of 12 and 20. But the study did not mea­sure vi­sion loss as its pri­ma­ry end­point, be­cause the dis­ease is grad­ual and vi­sion changes oc­cur over many years. Over the two-year pe­ri­od of the study, both the treat­ment and place­bo groups showed very lit­tle change in their abil­i­ty to see based on a fre­quent­ly used mea­sure called BC­VA.

Janux Ther­a­peu­tics’ lead T cell en­gager has shown re­sponse rates of 30% in a new da­ta cut from an ear­ly-stage study in prostate can­cer.

The prod­uct, named JANX007, is in a Phase 1 tri­al called EN­GAGER-PS­MA-01 in metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer (mCR­PC). A year ago, the com­pa­ny re­leased pos­i­tive ear­ly re­sults from 16 pa­tients in this tri­al, lead­ing the com­pa­ny’s stock to climb 66%.

On Mon­day, Janux post­ed up­dat­ed re­sults from 104 pa­tients who were treat­ed in the Phase 1a dose es­ca­la­tion part of the EN­GAGER tri­al. Janux al­so dis­closed da­ta on five pa­tients in a Phase 1b ex­pan­sion of the study. In both parts, JANX007 — which tar­gets PS­MA and CD3 — was in­fused ei­ther week­ly or every two weeks.